Page 2 - Laura Gault News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Laura gault. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Laura Gault Today - Breaking & Trending Today

Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington's Disease Seite 1

18.10.2023 - Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to SAGE-718 for the . Seite 1 ....

United States , Laura Gault , Sage Therapeutics Inc , Drug Administration , Office Of Orphan Products Development , Sage Therapeutics , Orphan Drug Designation , Chief Medical Officer , Orphan Products Development , Orphan Drug Act , Sage Therapeutics Chart , Age Therapeutics Kurs , Age Therapeutics Aktie ,

Sage Therapeutics Implements Strategic Reorganization to Support Plans for ZURZUVAE™ Commercial Launch and Pipeline Advancement

Potential growth catalysts include planned 4Q 2023 launch of ZURZUVAE and expected data read-outs for SAGE-718 and SAGE-324 in 2024

Approximately 40% workforce reduction supports focus on agile. ....

Jim Doherty , Laura Gault , Barry Greene , Al Robichaud , Chris Benecchi , Discovery Research , Exchange Commission , Clinical Development , Sage Therapeutics Inc , Osage Research , Sage Therapeutics , Chief Executive Officer , Chief Scientific Officer , Medicinal Chemistry , Pre Clinical Scientific Advisory , Mike Quirk , Chief Scientific , Non Clinical Development , Chief Development Officer , Chief Medical Officer , Chief Business Officer , Medical Affairs , Mark Pollack , Private Securities Litigation Reform Act ,

SAGE Therapeutics (SAGE) Implements Strategic Reorganization to Support Plans for ZURZUVAE Commercial Launch

SAGE Therapeutics (SAGE) Implements Strategic Reorganization to Support Plans for ZURZUVAE Commercial Launch
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jim Doherty , Chris Benecchi , Matthew Henson , Laura Gault , Ashley Kaplowitz , Al Robichaud , Barry Greene , Sage Therapeutics Inc , Clinical Development , Exchange Commission , Discovery Research , Osage Research , Sage Therapeutics , Chief Executive Officer , Chief Scientific Officer , Medicinal Chemistry , Pre Clinical Scientific Advisory , Mike Quirk , Chief Scientific , Non Clinical Development , Chief Development Officer , Chief Medical Officer , Chief Business Officer , Medical Affairs , Mark Pollack , Private Securities Litigation Reform Act ,

Sage cuts 40% of staff in portfolio shake-up (NASDAQ:SAGE)

Sage cuts 40% of staff in portfolio shake-up (NASDAQ:SAGE)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , Jim Doherty , Laura Gault , Al Robichaud , Chris Benecchi , Discovery Research , Chief Scientific Officer Al Robichaud , Chief Development Officer Jim Doherty , Mike Quirk , Chief Scientific Officer , Chief Medical Officer , Chief Business Officer , Medical Affairs , Mark Pollack ,

Sage Therapeutics to lay off about 40 percent of its workforce

The job cuts come after the FDA gave only limited approval to the Cambridge company’s new treatment for depression. ....

United States , Laura Gault , Chris Benecchi , Jim Doherty , Al Robichaud , Drug Administration , Centers For Disease , National Institute Of Mental Health , Mike Quirk , Mark Pollack , Disease Control , National Institute ,